4 pharmaceutical companies recall Ginkgo biloba

Recently, the State Food and Drug Administration found that some drug manufacturers have changed the extraction process without authorization, added related substances illegally, and purchased Ginkgo biloba extract from unqualified enterprises, and carried out actions in this regard On June 3, Guangdong food and Drug Administration released the announcement on the recall of ginkgo leaf drugs by drug manufacturers in Guangdong Province on its official website, announcing the recall of ginkgo leaf drugs by four drug manufacturers involved in the incident in Guangdong Province The State Food and Drug Administration recently found in the flight inspection of enterprises selling Ginkgo biloba drugs at low prices that some ginkgo biloba drug manufacturers have changed the extraction process of Ginkgo biloba leaves from dilute ethanol extraction to 3% hydrochloric acid extraction, and at the same time, they have never purchased the Ginkgo biloba extract produced by hydrochloric acid process from unqualified enterprises, which is used to produce Ginkgo biloba drugs, and purchased Serious illegal activities such as selling extracts to other pharmaceutical manufacturers, forging raw material purchase account and production inspection record, etc The regulatory authorities have successively found out that the relevant problems of Ginkgo biloba extract logistics have entered many domestic Ginkgo biloba drug manufacturers and Ginkgo biloba extract manufacturers, including Guangdong Xinfeng Pharmaceutical Co., Ltd., Guangdong Yili Luoding Pharmaceutical Co., Ltd., Guangdong universal Pharmaceutical Co., Ltd and Shenzhen Haiwang Pharmaceutical Co., Ltd The production of Ginkgo biloba extract by hydrochloric acid process can decompose the effective components of drugs and affect the efficacy of drugs The State Food and drug administration has issued a continuous document recently, deploying a comprehensive sampling inspection of Ginkgo biloba drugs, and requiring local food and drug regulatory departments to be responsible for supervising enterprises and units in their respective administrative regions to do a good job in drug recall According to the requirements of the State Food and drug administration, the provincial food and Drug Administration issued the notice on special treatment of Ginkgo biloba drugs to the whole province on May 21, and comprehensively launched the recall of Ginkgo biloba drugs related to drug manufacturers listed in the notice of the State Food and drug administration At the same time, the provincial food and drug administration requires the food and drug administration at all levels to urge all ginkgo leaf manufacturers within their jurisdiction to carry out self inspection and take the initiative to take product recall measures Enterprises that take the initiative to recall but do not recall completely and still find unqualified products in the future market sampling inspection will be dealt with strictly according to law According to the announcement of the provincial food and drug administration, as of June 3, four related drug enterprises in our province have recalled the problem Ginkgo biloba drugs Some enterprises have increased the comprehensive recall of all batches of Ginkgo biloba leaves and Ginkgo biloba dispersible tablets within the validity period on the basis of the relevant batches of Ginkgo leaves involved in the announcement of the previous recall supervision department.